DR. JOSEPH KANNARKATT M.D. NPI 1124311956

NPI Details

DR. Joseph Kannarkatt, M.D. is a hematology and oncology internal medicine in York, PA with 15 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Joseph Kannarkatt, M.D. NPI is 1124311956. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: JEFFERSON MEDICAL COLLEGE OF THOMAS JEFFERSON UNIVERSITY
Graduation Year:2011

The provider's business location address is:

25 MONUMENT RD STE 294
YORK, PA
ZIP 17403-049
Phone: (717) 851-4751

The NPI 1124311956 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, ferric derisomaltose, 10 mg (HCPCS:J1437)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg (HCPCS:Q5108)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Magnesium level (HCPCS:83735)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Ferritin (blood protein) level (HCPCS:82728)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Urinalysis, manual test (HCPCS:81002)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Unclassified drugs (HCPCS:J3490)
• Calcium level, total (HCPCS:82310)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Uric acid level, blood (HCPCS:84550)

The enumeration date for this NPI number is 5/26/2011 and was last updated on 3/17/2018.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: